- Home
- RSSS vs BCAB Comparison
RSSS vs BCAB Comparison
Compare RSSS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSSS
- BCAB
- Stock Information
- Founded
- RSSS 2006
- BCAB 2007
- Country
- RSSS United States
- BCAB United States
- Employees
- RSSS N/A
- BCAB N/A
- Industry
- RSSS Business Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- RSSS Consumer Discretionary
- BCAB Health Care
- Exchange
- RSSS Nasdaq
- BCAB Nasdaq
- Market Cap
- RSSS 110.0M
- BCAB 40.5M
- IPO Year
- RSSS N/A
- BCAB 2020
- Fundamental
- Price
- RSSS $3.29
- BCAB $0.71
- Analyst Decision
- RSSS Strong Buy
- BCAB Hold
- Analyst Count
- RSSS 1
- BCAB 3
- Target Price
- RSSS $5.00
- BCAB $1.00
- AVG Volume (30 Days)
- RSSS 76.2K
- BCAB 1.5M
- Earning Date
- RSSS 11-13-2025
- BCAB 11-05-2025
- Dividend Yield
- RSSS N/A
- BCAB N/A
- EPS Growth
- RSSS N/A
- BCAB N/A
- EPS
- RSSS 0.04
- BCAB N/A
- Revenue
- RSSS $49,057,981.00
- BCAB $11,000,000.00
- Revenue This Year
- RSSS $5.79
- BCAB N/A
- Revenue Next Year
- RSSS $8.46
- BCAB N/A
- P/E Ratio
- RSSS $82.25
- BCAB N/A
- Revenue Growth
- RSSS 9.94
- BCAB N/A
- 52 Week Low
- RSSS $2.32
- BCAB $0.24
- 52 Week High
- RSSS $4.24
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- RSSS 45.69
- BCAB 49.29
- Support Level
- RSSS $3.19
- BCAB $0.61
- Resistance Level
- RSSS $3.54
- BCAB $1.06
- Average True Range (ATR)
- RSSS 0.13
- BCAB 0.13
- MACD
- RSSS -0.03
- BCAB -0.02
- Stochastic Oscillator
- RSSS 33.62
- BCAB 21.05
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.